Navigation Links
Increasing Breast Density Significantly Impacts Breast Cancer Screening Performance
Date:1/30/2017

WELLINGTON, New Zealand, Jan. 30, 2017 /PRNewswire/ -- In the first large-scale study of its kind, Dutch researchers demonstrated a strong linear relationship between decreased screening performance and volumetric breast density.  Involving more than 110,000 mammograms from the Dutch Breast Screening Program (Foundation of Population Screening Mid-West), the study showed that increasing volumetric breast density, automatically measured by Volpara®Density™ software, impacts mammography performance measures, such as sensitivity and the rates of recall, false positives, and interval cancers.

The study, "Volumetric breast density affects performance of digital screening mammography," was recently published in Breast Cancer Research and Treatment (DOI: 10.1007/s10549-016-4090-7) and was carried out in the EU-funded ASSURE project  The results suggest that, since fully automated measurements of breast density have much higher reproducibility than visual assessment, this automatic method could help with implementing density-based supplemental screening.

In the study, Dr Carla van Gils and a team of researchers from the Netherlands examined screening performance in the Dutch Screening Program using a consecutive series of 111,898 digital mammograms from 53,239 women (age 50–75 years). Volumetric breast density was automatically assessed using VolparaDensity software, which automatically generates an objective measurement of volumetric breast density.

"There have been several studies that have demonstrated the impact of breast density on the sensitivity of mammography, including a recent study published in the American Journal of Roentgenology1 that showed a strong linear relationship between volumetric breast density and sensitivity.  However, this is the first large-scale study to also demonstrate a strong relationship between volumetric density and other screening performance measures like recall rate, false positives or interval cancers," said Dr van Gils.  "With the high reproducibility of the automatic VolparaDensity software, this could help with evaluating risk and better inform clinical decisions about adjunctive screening options based on women's specific density and other risk factors."

The study included 667 screen-detected and 234 interval cancers. Of all the tumors, 84.3% were invasive cancers.  Mammographic sensitivity was 85.7%, 77.6%, 69.5%, and 61.0% across VDG categories 1-4, respectively.  Increasing breast density showed a strong linear relationship to all screening performance measures, except positive predictive value.  The rates for recalls, false positives, and total and interval breast cancers in higher breast density categories were greater than those in lower density categories. Results demonstrated that a woman was nearly seven times more likely (4.4/1000 examinations versus 0.7/1000) to have an interval cancer if her breasts were extremely dense (VDG4) versus very fatty (VDG1) and approximately twice as likely (23.8/1000 examinations versus 11.2/1000) to have a false-positive if they were extremely dense (VDG4) versus very fatty (VDG1).

According to Dr van Gils, another interesting finding is the relationship between cancer type (in situ or invasive), breast density and detection mode (screen-detected or interval).  When only invasive breast cancer was taken into account, the difference in sensitivity between the density categories was even more pronounced.

"This indicates that the detection of invasive breast cancers in screening is hampered to a larger extent than the detection of in situ breast cancers. A possible explanation for this is that the visibility of microcalcifications is not hampered as much in dense tissue as the visibility of invasive breast cancers," added Dr van Gils.  "Studying this relationship further could be very important as we further develop our understanding of the effectiveness of screening."

About Volpara Solutions

Founded with the goal of helping radiologists give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Volpara Health Technologies Limited of New Zealand (formerly Matakina Technology). Available in most markets where breast cancer screening is commonplace, VolparaDensity provides an objective volumetric measure of breast density from both digital mammography and tomosynthesis data. VolparaDensity software is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient-specific x-ray dose, breast compression, breast positioning, and other factors designed to provide critical insight for breast imaging workflow. For more information, visit www.volparasolutions.com.

1 "Using volumetric breast density to quantify the potential masking risk of mammographic density," published in the American Journal of Roentgenology (AJR) (DOI:10.2214/AJR.16.16489)

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/increasing-breast-density-significantly-impacts-breast-cancer-screening-performance-300398295.html


'/>"/>
SOURCE Volpara Solutions
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth
2. Increasing Demand from End-user Applications Boosts Asia-Pacific Antimicrobial Coatings Market, Finds Frost & Sullivan
3. Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
4. Increasing Affluence and Legislative Reforms are Transforming Polands Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies
5. The Systemic Lupus Erythematosus Market Will Grow Dramatically Over the Next Decade, Increasing from Approximately $900 Million in 2012 to $4 Billion in 2022
6. First Financial Expands into Canada to Meet Increasing Demand for its Leasing Solutions
7. Pressure Relief Devices Market to 2019 - Increasing Focus on Pressure Ulcer Prevention and Quality of Care to Drive Growth: Industry Analysis, Size, Share, Growth, Trends and Forecast Now Available at MarketResearchReports.biz
8. Increasing Use of Allergans Botox and the Launch of Novel Nontriptan Products Will Be Key Drivers of Migraine Market Growth Through 2022
9. Surveyed Oncologists Indicate that the Use of Biomarker Testing is Increasing Rapidly in Non-Small-Cell Lung Cancer in China and South Korea
10. Despite Increasing Cost Sensitivity of EU5 Payers, Sofosbuvir and Simeprevir are Poised to Reshape the Hepatitis C Virus Market by End of 2015
11. The Asthma Drug Market Will Remain Relatively Flat, Increasing Slightly from $15.3 Billion in 2012 to $16.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... , Aug. 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Joel Saban as president, effective Aug. 7, 2017. ... has decided to pursue other interests and will serve as ... tenure, Paul has served us in multiple leadership roles since ... in Jun. 2015 and has provided decisive, strategic leadership which ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
(Date:8/2/2017)... Flight Network and PeaceHealth Oregon Network announced they renewed a ... efficiency for patients at hospitals in Eugene ... , and Florence, Oregon , who ... work collaboratively to move patients who require the highest level ... emergency exists. PeaceHealth ...
Breaking Medicine Technology:
(Date:8/21/2017)... , ... August 21, 2017 , ... ... events taking place all over the country. , Outdoor running increases exposure to ... are at an increased risk of melanoma, and only half may be adequately ...
(Date:8/21/2017)... ... ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse Executive at ... Trustees for a three-year term beginning January 1, 2018. , The AHA ... committed to the improvement of health in their communities. Founded in 1898, the AHA ...
(Date:8/20/2017)... ... August 20, 2017 , ... A total solar eclipse will occur across the U.S. ... the moon moves between the sun and Earth. This rare event will be magnificent to ... help keep you safe on the road during the total eclipse of the sun. , ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... Ed Begley, Jr., will feature the Aurum Group in an upcoming episode, slated ... This segment of Innovations will feature the Aurum Group; a company committed to ...
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health and telemedicine ... pending recognition status from the Centers for Disease Control and Prevention (“CDC”) to ... live video conferencing. , The DPP resulted from clinical work conducted by ...
Breaking Medicine News(10 mins):